Dr Reddy's Launches Seizures Treatment Tablets In US

New Delhi: Pharmaceuticals major Dr Reddy's Laboratories on Monday said it has launched generic Lamotrigine orally disintegrating tablets used for treatment of certain types of seizures in epileptic patients in the US market.

Dr Reddy's Laboratories said in a filing to the BSE that the tablets are in the strengths of 25 mg, 50 mg, 100 mg and 200 mg.

The company's product is a generic version of GSK Group of companies' Lamictal tablets, it added.

"The Lamictal ODT brand and generic had US sales of approximately $65.5 million MAT for the most recent twelve months ending July 2016 according to IMS Health," Dr Reddy's Laboratories said.

Lamictal is indicated as adjunctive therapy for the certain type of seizures and for the maintenance treatment of bipolar disorder. 

Shares in Dr Reddy's ended 0.80 per cent higher at Rs 3,078.65 apiece on the BSE, whose benchmark Sensex index finished up 0.08 per cent.